Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Accumulated Expenses (2016 - 2025)

VYNE Therapeutics' Accumulated Expenses history spans 10 years, with the latest figure at $941000.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 34.1% year-over-year to $941000.0; the TTM value through Dec 2025 reached $941000.0, down 34.1%, while the annual FY2025 figure was $941000.0, 34.1% down from the prior year.
  • Accumulated Expenses reached $941000.0 in Q4 2025 per VYNE's latest filing, up from $819000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $10.1 million in Q2 2021 to a low of $376000.0 in Q1 2024.
  • Average Accumulated Expenses over 5 years is $3.1 million, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: tumbled 84.2% in 2022, then soared 1723.94% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $2.8 million in 2021, then surged by 59.19% to $4.4 million in 2022, then tumbled by 62.45% to $1.6 million in 2023, then fell by 13.19% to $1.4 million in 2024, then crashed by 34.1% to $941000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Accumulated Expenses are $941000.0 (Q4 2025), $819000.0 (Q2 2025), and $6.9 million (Q1 2025).